SIRT1 and COVID-19: Collectively, these natural SIRT1 activators hold significant promise as adjunctive therapies in COVID‐19, yet comprehensive in vivo studies and large‐scale, well‐designed clinical trials remain essential to establish their efficacy, optimal dosing, and mechanisms of action in the context of SARS‐CoV‐2 infection [135].